YSPSAH Stock Overview
Y.S.P. Southeast Asia Holding Berhad, together with its subsidiaries, manufactures and sells pharmaceutical products.
Y.S.P. Southeast Asia Holding Berhad Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||RM2.05|
|52 Week High||RM2.39|
|52 Week Low||RM1.88|
|1 Month Change||8.47%|
|3 Month Change||5.13%|
|1 Year Change||3.54%|
|3 Year Change||-14.94%|
|5 Year Change||-32.34%|
|Change since IPO||14.41%|
Recent News & Updates
|YSPSAH||MY Pharmaceuticals||MY Market|
Return vs Industry: YSPSAH exceeded the MY Pharmaceuticals industry which returned -3.9% over the past year.
Return vs Market: YSPSAH exceeded the MY Market which returned -3.5% over the past year.
|YSPSAH Average Weekly Movement||2.7%|
|Pharmaceuticals Industry Average Movement||3.9%|
|Market Average Movement||5.5%|
|10% most volatile stocks in MY Market||11.7%|
|10% least volatile stocks in MY Market||2.7%|
Stable Share Price: YSPSAH is less volatile than 75% of MY stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: YSPSAH's weekly volatility (3%) has been stable over the past year.
About the Company
Y.S.P. Southeast Asia Holding Berhad, together with its subsidiaries, manufactures and sells pharmaceutical products. The company operates in three segments: Manufacturing, Trading, and Investment Holding. It manufactures, sells, trades in, and distributes pharmaceutical and veterinary products, pharmaceutical fine chemicals, raw material, health food products, and medical devices.
Y.S.P. Southeast Asia Holding Berhad Fundamentals Summary
|YSPSAH fundamental statistics|
Is YSPSAH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|YSPSAH income statement (TTM)|
|Cost of Revenue||RM174.45m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.13|
|Net Profit Margin||6.47%|
How did YSPSAH perform over the long term?See historical performance and comparison
3.9%Current Dividend Yield
Is YSPSAH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for YSPSAH?
Other financial metrics that can be useful for relative valuation.
|What is YSPSAH's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does YSPSAH's PE Ratio compare to its peers?
|YSPSAH PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
KOTRA Kotra Industries Berhad
RHONEMA Rhone Ma Holdings Berhad
DPHARMA Duopharma Biotech Berhad
AHEALTH Apex Healthcare Berhad
YSPSAH Y.S.P. Southeast Asia Holding Berhad
Price-To-Earnings vs Peers: YSPSAH is good value based on its Price-To-Earnings Ratio (15.3x) compared to the peer average (16.3x).
Price to Earnings Ratio vs Industry
How does YSPSAH's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?
Price-To-Earnings vs Industry: YSPSAH is expensive based on its Price-To-Earnings Ratio (15.3x) compared to the MY Pharmaceuticals industry average (14.2x)
Price to Earnings Ratio vs Fair Ratio
What is YSPSAH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||15.3x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate YSPSAH's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of YSPSAH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: YSPSAH (MYR2.05) is trading below our estimate of fair value (MYR17.22)
Significantly Below Fair Value: YSPSAH is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Y.S.P. Southeast Asia Holding Berhad forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Y.S.P. Southeast Asia Holding Berhad has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine whether Y.S.P. Southeast Asia Holding Berhad is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
How has Y.S.P. Southeast Asia Holding Berhad performed over the past 5 years?
Past Performance Score1/6
Past Performance Score 1/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: YSPSAH has high quality earnings.
Growing Profit Margin: YSPSAH's current net profit margins (6.5%) are lower than last year (6.6%).
Past Earnings Growth Analysis
Earnings Trend: YSPSAH's earnings have declined by 10% per year over the past 5 years.
Accelerating Growth: YSPSAH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: YSPSAH had negative earnings growth (-0.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (21.4%).
Return on Equity
High ROE: YSPSAH's Return on Equity (5.3%) is considered low.
Discover strong past performing companies
How is Y.S.P. Southeast Asia Holding Berhad's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: YSPSAH's short term assets (MYR320.1M) exceed its short term liabilities (MYR66.4M).
Long Term Liabilities: YSPSAH's short term assets (MYR320.1M) exceed its long term liabilities (MYR34.0M).
Debt to Equity History and Analysis
Debt Level: YSPSAH has more cash than its total debt.
Reducing Debt: YSPSAH's debt to equity ratio has increased from 5.2% to 9.9% over the past 5 years.
Debt Coverage: YSPSAH's debt is well covered by operating cash flow (169.5%).
Interest Coverage: YSPSAH's interest payments on its debt are well covered by EBIT (26.1x coverage).
Discover healthy companies
What is Y.S.P. Southeast Asia Holding Berhad current dividend yield, its reliability and sustainability?
Dividend Score 5/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: YSPSAH's dividend (3.9%) is higher than the bottom 25% of dividend payers in the MY market (2%).
High Dividend: YSPSAH's dividend (3.9%) is low compared to the top 25% of dividend payers in the MY market (4.87%).
Stability and Growth of Payments
Stable Dividend: YSPSAH's dividends per share have been stable in the past 10 years.
Growing Dividend: YSPSAH's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (52.3%), YSPSAH's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (18.7%), YSPSAH's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Fang-Hsin Lee (62 yo)
Dr. Fang-Hsin Lee serves as Director of Yung Shin Pharm. Ind. Co., Ltd.He serves as a Director at Vetnostrum Animal Health Co., Ltd. He serves as Supervisor of Chemix Inc. since March 18, 2022. He has bee...
Experienced Management: YSPSAH's management team is seasoned and experienced (15.6 years average tenure).
Experienced Board: YSPSAH's board of directors are seasoned and experienced ( 17 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Y.S.P. Southeast Asia Holding Berhad's employee growth, exchange listings and data sources
- Name: Y.S.P. Southeast Asia Holding Berhad
- Ticker: YSPSAH
- Exchange: KLSE
- Founded: 1987
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: RM289.077m
- Shares outstanding: 141.01m
- Website: https://www.yspsah.com
- Y.S.P. Southeast Asia Holding Berhad
- Menara LGB
- Level 22
- Kuala Lumpur
- Wilayah Persekutuan
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/14 00:00|
|End of Day Share Price||2022/08/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.